Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell Frequency in the HOVON-SAKK132 Trial

Zeijlemaker W, Kelder A, Oussoren-Brockhoff Y, Scholten W, Snel A, Veldhuizen D . A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2015; 30(2):439-46. DOI: 10.1038/leu.2015.252. View

Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L . 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767. PMC: 8718623. DOI: 10.1182/blood.2021013626. View

Zeijlemaker W, Kelder A, Cloos J, Schuurhuis G . Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia. Curr Protoc Cytom. 2019; 91(1):e66. PMC: 6856793. DOI: 10.1002/cpcy.66. View

Manobianco S, Rakiewicz T, Wilde L, Palmisiano N . Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia. Front Oncol. 2022; 12:892289. PMC: 9336463. DOI: 10.3389/fonc.2022.892289. View

Al-Mawali A, Pinto A, Al-Zadjali S . CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection. Acta Haematol. 2017; 138(3):175-181. PMC: 5804858. DOI: 10.1159/000480448. View

Lowenberg B, Pabst T, Maertens J, Gradowska P, Biemond B, Spertini O . Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021; 5(4):1110-1121. PMC: 7903238. DOI: 10.1182/bloodadvances.2020003855. View

Zeijlemaker W, Kelder A, Wouters R, Valk P, Witte B, Cloos J . Absence of leukaemic CD34 cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered. Br J Haematol. 2015; 171(2):227-238. DOI: 10.1111/bjh.13572. View

Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham J . CD34CD38 leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia. 2018; 33(5):1102-1112. DOI: 10.1038/s41375-018-0326-3. View

Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M . Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. Am J Hematol. 2017; 92(4):388-396. DOI: 10.1002/ajh.24663. View

10.

Cloos J, Harris J, Janssen J, Kelder A, Huang F, Sijm G . Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. J Vis Exp. 2018; (133). PMC: 5931431. DOI: 10.3791/56386. View

11.

Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P . High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World J Stem Cells. 2018; 9(12):227-234. PMC: 5746643. DOI: 10.4252/wjsc.v9.i12.227. View

12.

Czyz A, Nagler A . The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. Int J Mol Sci. 2019; 20(21). PMC: 6862140. DOI: 10.3390/ijms20215362. View

13.

Terwijn M, Zeijlemaker W, Kelder A, Rutten A, Snel A, Scholten W . Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014; 9(9):e107587. PMC: 4171508. DOI: 10.1371/journal.pone.0107587. View

14.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

15.

Li S, Xu L, Wang Y, Zhang X, Chen H, Chen Y . An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood. 2022; 140(5):516-520. DOI: 10.1182/blood.2021014604. View

16.

Hanekamp D, Denys B, Kaspers G, Te Marvelde J, Schuurhuis G, de Haas V . Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. Br J Haematol. 2017; 183(3):512-516. DOI: 10.1111/bjh.14991. View

17.

Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau M, Rieu J . Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia. Clin Cancer Res. 2022; 29(1):134-142. DOI: 10.1158/1078-0432.CCR-22-2237. View

18.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

19.

Herold T, Rothenberg-Thurley M, Grunwald V, Janke H, Goerlich D, Sauerland M . Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020; 34(12):3161-3172. PMC: 7685975. DOI: 10.1038/s41375-020-0806-0. View

20.

Palmieri R, Buccisano F, Arena V, Consalvo M, Piciocchi A, Maurillo L . CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. Leuk Lymphoma. 2021; 63(4):996-1000. DOI: 10.1080/10428194.2021.2005042. View